RxDoctor Payments Data

Denise Foster, PA

Medical · Bowling Green, MONPI 1497814289

Payments from drug & device makers

$1,200in general payments, 2019–2025

Across 40 payments — averaging $29.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$265
  • AbbVie$226
  • Neurocrine Biosciences, Inc.$194
  • Teva Pharmaceuticals USA, Inc.$176
  • Otsuka America Pharmaceutical, Inc.$116
  • Pfizer$48
  • plus $174 from 8 others

What the payments were for

  • Food & beverage$1,08891%
  • Education$1119%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,200 in reported general payments places this provider in the 65th percentile of 198 medical providers in Missouri.

See all medical providers in Missouri

Medicare billing

Part B allowed, 2024
$493
Medicare patients
26
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$27,103
OzempicSemaglutide25$25,488
TrulicityDulaglutide18$17,260
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$6,935
Novolog FlexpenInsulin Aspart15$2,058
BreynaBudesonide/Formoterol Fumarate13$1,834
Atorvastatin Calcium170$1,289
Levothyroxine Sodium160$1,061
Omeprazole72$1,055
Tramadol Hcl59$980
Albuterol Sulfate HfaAlbuterol Sulfate42$871
Lisinopril135$861
Losartan Potassium73$840
Ventolin HfaAlbuterol Sulfate11$825
Metformin Hcl92$820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$38$25,48825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 198 medical providers in Missouri.

Other medical in Bowling Green

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →